---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-037861"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:19:25.124608+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma raises ~$15M in registered direct offering of common stock and warrants

## Summary
- Sold 21.43M shares and warrants to buy 21.43M shares at $0.70/combined unit.
- Warrants exercisable at $0.75/share from 6 months after issuance, expire in 5 years.
- Gross proceeds ~$15M; net proceeds ~$13.8M after placement agent fees and expenses.
- Proceeds for general corporate purposes, including pre-clinical/clinical development and working capital.
- Offering closed April 30, 2024; H.C. Wainwright acted as exclusive placement agent.

## SEC filing metadata
- accession: 0001213900-24-037861
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390024037861/0001213900-24-037861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390024037861/ea0204892-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-037861
- JSON: https://secwatch.observer/filing/0001213900-24-037861.json
- Plain text: https://secwatch.observer/filing/0001213900-24-037861.txt

## Key facts
- Material Agreements
  Citius Pharmaceuticals, Inc. entered into Purchase Agreement with certain institutional investors (effective 2024-04-25).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Effective: 2024-04-25
  source text: On April 25, 2024, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 21,428,574 shares of the Company’s common stock, par value $0.001 per share (the “Shares”) and warrants (the “Warrants”) to purchase up to 21,428,574 shares of common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390024037861/0001213900-24-037861-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.